Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab

NCT05626855 is registered in ClinicalTrials.gov with Scholar Rock, Inc. as lead sponsor.

NCT NCT05626855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05626855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab
Lead sponsor
Scholar Rock, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 17, 2023
Completion date
May 2, 2029
Enrollment
238 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

anti-myostatin, atrophy, muscular atrophy, muscular atrophy, spinal, neuromuscular diseases, neuromuscular manifestations, sma, spinal muscular atrophy, spinal muscular atrophy type 2, spinal muscular atrophy type 3